glp 1 nhs Weight Loss Injection/ GLP-1 NHS faces GLP-1 agonist shortage

In major clinical trials, such as the landmark STEP 1 trial published in the New England Journal of Medicine , a once-weekly injection of semaglutide 2.4 mg resulted in an average body weight reduction of roughly 14.9% over 68 weeks

Bezin J., Gouverneur A., Pnichon M., et al., GLP1 Receptor Agonists and the Risk of Thyroid Cancer, Diabetes Care 46 (2022): 384390

Many patients report that this simplicity supports better adherenceand better adherence leads to better outcomes

1 Pancreatic Endocrine and Exocrine Actions of GLP-1 on Islet and Acinar Cells (Drucker DJ

Taking GLP-1s has been shown to reduce markers of inflammation